This newest report from Medtech Insight provides the U.S. market forecast for tissue-engineered skin replacement and substitute products for the years 2009 to 2014, an estimation of the potential market for the years 2009 and 2019, and a competitive analysis (including market shares for the leading suppliers to this market). In addition, this new report also provides an overview of tissue-engineered skin replacement and substitutes currently being marketed in the U.S., an update on emerging products as well as a clinical overview of the primary clinical applications for tissue-engineered skin replacements and substitutes (including up-to-date incidence and prevalence numbers for associated diseases).
This is the final report in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. Previous reports in this series have provided analyses of the U.S. markets for cardiac and vascular, musculoskeletal, neurosurgical, urologic, and organ regeneration tissue engineering and cell transplantation products.
EXECUTIVE SUMMARY i. Selected Clinical Applications for Skin Replacements and Substitutes a. Burns b. Skin Ulcers c. Plastic Surgery d. Inguinal Herniorrhaphy ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Skin Replacement and Substitute Products iv. Market Analysis a. Market Drivers b. Market Limiters v. Methodology Exhibit ES-1: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures Exhibit ES-2: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019 Exhibit ES-3: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014 1. CLINICAL OVERVIEW 1.1 Layers of the Skin and Supporting Structures 1.1.1 Epidermis 1.1.2 Dermis 1.1.3 Subcutaneous Tissue 1.1.4 Fascia 1.1.5 Muscle 1.1.6 Bone 1.2 Selected Clinical Applications for Skin Replacements and Substitutes 1.2.1 Burns 1.2.2 Skin Ulcers 184.108.40.206 Diabetic Ulcers 220.127.116.11 Pressure Ulcers 18.104.22.168 Venous Stasis Ulcers 1.2.3 Plastic Surgery 1.2.4 Inguinal Herniorrhaphy Exhibit 1-1: The Skin's Layers and Supporting Structures Exhibit 1-2: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures Exhibit 1-3: Stages of Burn Wounds Exhibit 1-4: Stages of Pressure Ulcers Exhibit 1-5: National Nursing Home Survey Regarding Pressure Ulcers 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 22.214.171.124 Collagen 126.96.36.199 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 188.8.131.52 Deoxyribonucleic Acid Transfection Vectors 184.108.40.206 Genetically Manipulated Cells 220.127.116.11 Three-Dimensional Polymer Technology 18.104.22.168 Transgenics 22.214.171.124 Fibroblasts 126.96.36.199 Immortalized Neural Stem Cells 188.8.131.52 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 184.108.40.206 Flatbed Perfusion Systems 220.127.116.11 Hollow Fiber Bioreactor Systems 18.104.22.168 Cell Suspension Systems 22.214.171.124 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. U.S. MARKETS FOR TISSUE-ENGINEERED SKIN REPLACEMENTS AND SUBSTITUTES 3.1 Allografts 3.2 Autografts 3.3 Xenografts 3.4 Amniotic Membranes 3.5 Skin Replacement and Substitute Products 3.5.1 Epidermal Equivalents 3.5.2 Dermal Equivalents 3.5.3 Composite Bilayer Skin Equivalents 3.5.4 Other Biological Products for Wound Care 3.6 Emerging Skin Replacement and Substitute Products 3.6.1 Emerging Epidermal Equivalents 3.6.2 Emerging Composite Bilayer Skin Equivalents 3.6.3 Other Emerging Biological Products for Wound Care 3.7 Market Analysis 3.7.1 Market Drivers 3.7.2 Market Limiters 3.8 Competitive Analysis Exhibit 3-1: Advantages and Disadvantages of Allografts Exhibit 3-2: 2010, Selected Dermal Equivalent Skin Substitutes Exhibit 3-3: 2010, Selected Composite Bilayer Equivalent Skin Substitutes Exhibit 3-4: 2010, Selected Emerging Epidermal Equivalent Products Exhibit 3-5: 2010, Selected Emerging Composite Bilayer Equivalent Products Exhibit 3-6: 2010, Selected Other Emerging Biological Wound Repair Products Exhibit 3-7: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019 Exhibit 3-8: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014 Exhibit 3-9: 2009, Tissue Engineered Skin Replacements and Substitutes Market, Share by Supplier 4. COMPANY PROFILES 4.1 Advanced BioHealing, Inc. 4.2 Cook Biotech, Inc./Cook Group, Inc. 4.3 Cytomedix, Inc. 4.4 Integra LifeSciences Corporation 4.5 LifeCell Corporation/Kinetic Concepts, Inc. 4.6 Organogenesis, Inc. 4.7 Soluble Systems LLC 4.8 Stemnion, Inc. 4.9 TEI Biosciences, Inc. 4.10 Wright Medical Group, Inc. APPENDIX: COMPANY LISTING